Dr. Falk Pharma

Name

Dr. Falk Pharma

Legal name

Dr. Falk Pharma GmbH

Website

https://drfalkpharma.com

Company type

Private

Founded year

1960

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Dr. Falk Pharma is a privately held, family-owned German specialty pharmaceutical company founded in 1960 that develops and commercializes topical gastrointestinal and hepatology medicines (Salofalk, Budenofalk, Ursofalk, Jorveza) across Europe, Australia, and Canada, serving patients with IBD, eosinophilic esophagitis, and cholestatic liver diseases.

Ownership category

akta.pro rank

Product category

Gastroenterology & Hepatology Pharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Gastroenterology Specialty Pharmaceuticals (HLAIACAE)

akta.pro secondary industries

Gastroenterology & Hepatology Pharmaceuticals (HLAIAAAI), General Gastroenterology (HLAKAEAA)

Keywords

• Gastroenterology pharmaceuticals
• Inflammatory bowel disease
• Hepatology drug treatments
• Digestive medicine therapies
• Cholestatic liver disease

Headquarters

HQ city

Freiburg Im Breisgau

HQ country

Germany

HQ region

Europe

Offices9 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Product Sales: Dr. Falk Pharma develops and commercializes innovative medicines for digestive and metabolic diseases. The company markets branded pharmaceutical products including Azafalk, Budenofalk, Endofalk, Jorveza, Mucofalk, Salofalk, and Ursofalk across Europe, Australia, and Canada.
2. Licensing and Development Agreements: The company generates revenue through licensing deals and co-development partnerships. In 2025, Merck paid $150M upfront for development and commercialization rights to MK-8690, with potential additional payments and royalties.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

Core offering

Dr. Falk Pharma is a research-based pharmaceutical company that develops, manufactures, and commercializes prescription medicines for digestive and metabolic diseases. Its portfolio focuses on topically acting drugs delivered to specific functional segments of the gastrointestinal tract, including treatments for inflammatory bowel disease (ulcerative colitis, Crohn's disease, microscopic colitis), eosinophilic esophagitis (Jorveza), and cholestatic liver diseases (Ursofalk for PBC). The company markets branded products such as Salofalk, Budenofalk, Jorveza, Ursofalk, Endofalk, Azafalk, and Mucofalk across Europe, Australia, and Canada.

Product overview

Dr. Falk Pharma is a research-based family business specializing in digestive and metabolic medicine, developing and distributing pharmaceutical products for inflammatory bowel disease (IBD), cholestatic liver diseases, eosinophilic esophagitis (EoE), and other gastroenterological conditions. The product portfolio includes core marketed brands such as Budenofalk® (budesonide), Salofalk® (mesalazine), Ursofalk® (ursodeoxycholic acid), Jorveza® (budesonide orodispersible tablet for EoE), Azafalk®, Endofalk®, and Mucofalk®, along with pipeline candidates including naronapride (Phase 3 for gastroparesis) and norursodeoxycholic acid (Phase 3 for PSC). The company operates globally with subsidiaries across Europe and partners with organizations including Renexxion Ireland and Merck for development programs.

Differentiator

Problem solved

Functional benefit

Brands

• Falk Foundation e.V. Scientific foundation that organizes and supports scientific dialogue to advance therapeutic progress in gastroenterology and hepatology. Facilitates exchange of knowledge through Falk Forums, Falk Futures, symposia, Falk Gastro Review Journal, and Falk Gastro Education.
• Jorveza®
• Corum

Products and services

• Salofalk
• Budenofalk
• Jorveza
• Ursofalk
• Endofalk
• Azafalk
• Mucofalk

Quantifiable outcome

• 58% of patients achieving clinico-pathological remission with JORVEZA
• +2 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Six partnerships are on record, tiered core, major and minor.

• Renexxion IrelandcoreStrategic or Co-development Partner · 1 June 2026Co-development partnership for naronapride (RWJ-355280), a pan-GI prokinetic with dual mechanism of action for gastroparesis treatment. Following positive Phase 2b MOVE-IT trial results (328 patients), the companies are advancing into pivotal Phase 3 studies with plans for regulatory-harmonized global development program for US and European approval.
• EwopharmamajorChannel Partner/ Reseller/ Distributor · 29 May 2026Renewed distribution partnership for Central Eastern Europe and Adriatics region, continuing long-standing collaboration for product distribution.
• Allianthera (Suzhou) BiopharmaceuticalscoreStrategic or Co-development Partner · 30 July 2025Strategic partnership for development of novel AhR (aryl hydrocarbon receptor) Agonist for treatment of moderate to severe ulcerative colitis.
• Kynos TherapeuticscoreStrategic or Co-development Partner · 29 October 2024Acquisition of Kynos Therapeutics, adding acute pancreatitis as a therapeutic focus and further strengthening development portfolio.
• Takeda and ZediramajorStrategic or Co-development Partner · 20 October 2022Collaboration and licensing agreement with Takeda and Zedira to develop first-in-class celiac disease therapy.
• ZediraminorStrategic or Co-development Partner · 1 July 2022Phase 2a proof of concept study of ZED1227 for treatment of non-alcoholic fatty liver disease (NAFLD).

Scale indicators10 records

Recent moves9 records

Expansion highlights6 records

Broad incumbents

• AbbVie: Global pharmaceutical major with significant gastroenterology exposure (Humira, Skyrizi, Rinvoq for IBD). Comparable as a broad incumbent in the same gastroenterology specialty space where Dr. Falk operates, though with a vastly larger portfolio and biologic focus vs. Dr. Falk's topical/small-molecule approach.
• Salix Pharmaceuticals: US-focused gastroenterology specialty pharmaceutical company (part of Bausch Health) with established IBD/IBS portfolio. Comparable as a GI specialty pharma pure-play, though serving primarily the US market that Dr. Falk does not directly address.
• Recordati: European specialty pharmaceutical group with gastroenterology and rare disease franchises. Comparable as a publicly-listed European mid-cap pharma with adjacent GI specialty exposure and similar distribution model across Europe.
• Gilead Sciences: Major biopharmaceutical company with hepatology franchise (viral hepatitis, PBC via CymaBay acquisition). Comparable as a competitor in liver disease therapeutics, with greater scale and biologic focus than Dr. Falk.
• Almirall: European specialty pharmaceutical company with gastroenterology (IBS, IBD) and dermatology franchises. Comparable as a European-based mid-sized specialty pharma with overlapping GI indications and similar geographic footprint.
• Allergan (now part of AbbVie): Historically a major specialty pharma with GI/IBS portfolio (Linzess, Viberzi) prior to AbbVie acquisition. Comparable in GI specialty pharmaceuticals across IBS and motility indications adjacent to Dr. Falk's gastroparesis work.

Direct peers

• Takeda Pharmaceutical: Major GI-focused pharmaceutical company with established gastroenterology franchise (Entyvio for IBD) and active co-development partner with Dr. Falk (Zedira celiac disease program). Directly comparable in gastroenterology specialty pharmaceuticals and global commercial reach.
• Ferring Pharmaceuticals: Privately-held research-driven pharmaceutical company headquartered in Switzerland with significant gastroenterology and hepatology portfolio. Highly comparable as a similarly-sized, family-controlled European pharma focused on GI/reproductive health.
• Intercept Pharmaceuticals: Specialty pharmaceutical company focused on liver diseases including PBC (Ocaliva) and NASH. Directly comparable in hepatology/cholestatic liver disease space, where Dr. Falk also markets Ursofalk for PBC and is developing norUDCA for PSC.
• Tillotts Pharma: Specialty pharmaceutical company focused exclusively on gastroenterology with IBD products (mesalazine-based therapies). Highly comparable as a mid-sized European GI specialty competitor with overlapping mesalazine franchise versus Dr. Falk's Salofalk.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xtwitter.com/DrFalkUK
• LinkedInlinkedin.com/company/dr.-falk-pharma/?miniCompanyUrn=urn%3Ali%3Afs_miniCompany%3A152904

Revenue estimate

Valuation estimate

Number of profiles

Profiles14 records

Subsidiaries5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Dr. Falk Pharma